{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T12:00:02Z","timestamp":1794484802606,"version":"4.9.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2011,7,27]],"date-time":"2011-07-27T00:00:00Z","timestamp":1311724800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1007\/s11883-011-0194-z","type":"journal-article","created":{"date-parts":[[2011,7,26]],"date-time":"2011-07-26T08:02:58Z","timestamp":1311667378000},"page":"422-430","source":"Crossref","is-referenced-by-count":5,"title":["The Role of Atherosclerosis Imaging in Redefining Normal and Abnormal Cholesterol Values, and Risk Reduction in Primary Prevention Statin Trials"],"prefix":"10.1007","volume":"13","author":[{"given":"Harvey S.","family":"Hecht","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,7,27]]},"reference":[{"key":"194_CR1","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jacc.2005.02.088","volume":"46","author":"Y Arad","year":"2005","unstructured":"Arad Y, Goodman KJ, Roth M, et al. Coronary calcification, coronary risk factors, and atherosclerotic cardiovascular disease events. The St. Francis Heart Study. J Am Coll Cardiol. 2005;46:158\u201365.","journal-title":"J Am Coll Cardiol"},{"key":"194_CR2","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1016\/j.jacc.2006.10.079","volume":"49","author":"MJ Budoff","year":"2007","unstructured":"Budoff MJ, Shaw LJ, Liu ST, et al. Long-term prognosis associated with coronary calcification: observations from a registry of 25,253 patients. J Am Coll Cardiol. 2007;49:1860\u201370.","journal-title":"J Am Coll Cardiol"},{"key":"194_CR3","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ahj.2007.08.024","volume":"155","author":"A Becker","year":"2008","unstructured":"Becker A, Leber A, Becker C, Knez A. Predictive value of coronary calcifications for future cardiac events in asymptomatic individuals. Am Heart J. 2008;155:154\u201360.","journal-title":"Am Heart J"},{"key":"194_CR4","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1056\/NEJMoa072100","volume":"358","author":"R Detrano","year":"2008","unstructured":"\u2022\u2022 Detrano R, Guerci AD, Carr JJ, et al. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N Engl J Med 2008;358:1336\u20131345. This landmark paper convincingly demonstrates the prognostic power of CAC and its superiority to risk factors.","journal-title":"N Engl J Med"},{"key":"194_CR5","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.jacc.2010.06.030","volume":"56","author":"R Erbel","year":"2010","unstructured":"\u2022\u2022 Erbel R, M\u00f6hlenkamp S, Moebus S, et al, for the Heinz Nixdorf Recall Study Investigative Group. Coronary risk stratification, discrimination, and reclassification improvement based on quantification of subclinical coronary atherosclerosis. The Heinz Nixdorf Recall Study. J Am Coll Cardiol 2010;56:1397\u20131406. This is the most recent and comprehensive demonstration of the superiority of CAC to risk factors for risk assessment.","journal-title":"J Am Coll Cardiol"},{"key":"194_CR6","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1016\/j.jacc.2009.11.075","volume":"55","author":"V Nambi","year":"2010","unstructured":"\u2022 Nambi V, Chambless L, Folsom AR, et al. Carotid intima-media thickness and presence or absence of plaque improves prediction of coronary heart disease risk:The ARIC (Atherosclerosis Risk In Communities). Study.J Am Coll Cardiol 2010;55:1600\u20137. These are the most recent and powerful data supporting the superiority of carotid intima-media thickening and plaque to risk factors.","journal-title":"J Am Coll Cardiol"},{"key":"194_CR7","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1016\/j.jacc.2010.07.005","volume":"56","author":"AJ Taylor","year":"2010","unstructured":"\u2022\u2022 Taylor AJ, Cerqueira M, Hodgson JM, et al ACCF\/SCCT\/ACR\/AHA\/ASE\/ASNC\/SCAI\/SCMR 2010 Appropriate Use Criteria for Cardiac Computed Tomography. J Am Coll Cardiol 2010; 56: 1864 \u2013 1894. This article defines the appropriate use of CAC.","journal-title":"J Am Coll Cardiol"},{"key":"194_CR8","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.1016\/j.jacc.2010.09.001","volume":"56","author":"P Greenland","year":"2010","unstructured":"\u2022\u2022 Greenland P, Alpert JS, Beller GA, et al. 2010 ACCF\/AHA Guideline for assessment of cardiovascular risk in adults. A report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2010;56:e50\u2013103. This guideline is the latest and most powerful endorsement of subclinical atherosclerosis for risk assessment in primary prevention.","journal-title":"J Am Coll Cardiol"},{"key":"194_CR9","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.amjcard.2008.06.028","volume":"102","author":"VE Friedewald","year":"2008","unstructured":"Friedewald VE, Ballantyne CM, Davidson MH, et al. The Editor\u2019s Roundtable: Lipid management beyond statins\u2014Reducing residual cardiovascular risk. Am J Cardiol. 2008;102:559\u201367.","journal-title":"Am J Cardiol"},{"key":"194_CR10","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.amjcard.2010.05.002","volume":"106","author":"VJ Carey","year":"2010","unstructured":"Carey VJ, Bishop L, Laranjo N, et al. Contribution of high plasma triglycerides and low high-density lipoprotein cholesterol to residual risk of coronary heart disease after establishment of low-density lipoprotein cholesterol control. Am J Cardiol. 2010;106:757\u201363.","journal-title":"Am J Cardiol"},{"key":"194_CR11","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.amjcard.2010.09.022","volume":"106","author":"WC Roberts","year":"2010","unstructured":"Roberts WC. It\u2019s the cholesterol, stupid. Am J Cardiol. 2010;106:1364\u20136.","journal-title":"Am J Cardiol"},{"key":"194_CR12","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1161\/CIRCULATIONAHA.104.512681","volume":"112","author":"P Raggi","year":"2005","unstructured":"Raggi P, Davidson M, Callister TQ, et al. Aggressive versus moderate lipid-lowering therapy in hypercholesterolemic post-menopausal women: beyond endorsed lipid lowering with EBT scanning (BELLES). Circulation. 2005;112:563\u201371.","journal-title":"Circulation"},{"key":"194_CR13","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jacc.2005.02.089","volume":"46","author":"Y Arad","year":"2005","unstructured":"Arad Y, Spadaro LA, Roth M, et al. Treatment of asymptomatic adults with elevated coronary calcium scores with atorvastatin, vitamin C, and vitamin E. The St. Francis Heart Study randomized clinical trial. J Am Coll Cardiol. 2005;46:166\u201372.","journal-title":"J Am Coll Cardiol"},{"key":"194_CR14","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1161\/CIRCULATIONAHA.105.568147","volume":"113","author":"A Schmermund","year":"2006","unstructured":"Schmermund A, Achenbach S, Budde T, et al. Effect of intensive versus standard lipid-lowering treatment with atorvastatin on the progression of calcified coronary atherosclerosis over 12\u00a0months. A multicenter, randomized, double-blind trial. Circulation. 2006;113:427\u201337.","journal-title":"Circulation"},{"key":"194_CR15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1161\/01.ATV.0000112102.28859.39","volume":"24","author":"P Raggi","year":"2004","unstructured":"Raggi P, Callister TQ, Shaw LJ. Progression of coronary artery calcium and risk of first myocardial infarction in patients receiving cholesterol-lowering therapy. Arterioscler Thromb Vasc Biol. 2004;24:1\u20137.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"194_CR16","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.jcmg.2010.08.018","volume":"3","author":"MJ Budoff","year":"2010","unstructured":"\u2022\u2022 Budoff MJ, Hokanson JE, Nasir K, et al. Progression of coronary artery calcium predicts all-cause mortality. J Am Coll Cardiol Img 2010;3:1229 \u20131236. This article is a convincing demonstration of the importance of tracking CAC progression.","journal-title":"J Am Coll Cardiol Img"},{"key":"194_CR17","first-page":"1383","volume":"344","author":"Scandinavian Simvastatin Survival Study Group","year":"1994","unstructured":"Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian SimvastatinSurvival Study (4S). Lancet. 1994;344:1383\u20139.","journal-title":"Lancet"},{"key":"194_CR18","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1161\/01.CIR.97.15.1446","volume":"97","author":"FM Sacks","year":"1998","unstructured":"Sacks FM, Moy\u00e9 LA, Davis BR, et al. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events Trial. Circulation. 1998;97:1446\u201352.","journal-title":"Circulation"},{"key":"194_CR19","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199811053391902","volume":"339","author":"The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) study group","year":"1998","unstructured":"The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) study group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349\u201357.","journal-title":"N Engl J Med"},{"key":"194_CR20","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","volume":"359","author":"PM Ridker","year":"2008","unstructured":"Ridker PM, Danielson E, Fonseca FAH, et al. For the JUPITER study group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195\u2013207.","journal-title":"N Engl J Med"},{"key":"194_CR21","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1161\/01.STR.27.3.480","volume":"27","author":"MA Espeland","year":"1996","unstructured":"Espeland MA, Craven TE, Riley WA, et al. Reliability of longitudinal ultrasonographic measurements of carotid intimal-medial thicknesses. Asymptomatic Caroti Artery Progression Study Research Group. Stroke. 1996;27:480\u20135.","journal-title":"Stroke"},{"key":"194_CR22","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s12410-009-0051-4","volume":"2","author":"HS Hecht","year":"2009","unstructured":"\u2022\u2022 Hecht HS. Naghavi M. Cardiovascular residual risk assessment in patients undergoing therapy: A combined structural and functional approach. Current Cardiovascular Imaging Reports 2009, 2: 405\u2013409. This article provides the theoretical framework for the redefinition of residual risk.","journal-title":"Current Cardiovascular Imaging Reports"},{"key":"194_CR23","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1067\/mhj.2001.113220","volume":"141","author":"P Raggi","year":"2001","unstructured":"Raggi P, Cooil B, Callister TQ. Use of electron beam tomography data to develop models for prediction of hard coronary events. Am Heart J. 2001;141:375\u201382.","journal-title":"Am Heart J"},{"key":"194_CR24","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1067\/mhj.2002.120409","volume":"143","author":"ND Wong","year":"2002","unstructured":"Wong ND, Budoff MJ, Pio J, Detrano RC. Coronary calcium and cardiovascular event risk: evaluation by age- and sex-specific quartiles. Am Heart J. 2002;143:456\u20139.","journal-title":"Am Heart J"},{"key":"194_CR25","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1161\/01.CIR.0000068341.61180.55","volume":"107","author":"GT Kondos","year":"2003","unstructured":"Kondos GT, Hoff JA, Sevrukov A, et al. Electron-beam tomography coronary artery calcium and cardiac events: a 37\u00a0month follow-up of 5635 initially asymptomatic low- to intermediate-risk adults. Circulation. 2003;107:2571\u20136.","journal-title":"Circulation"},{"key":"194_CR26","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1148\/radiol.2283021006","volume":"228","author":"LJ Shaw","year":"2003","unstructured":"Shaw LJ, Raggi P, Schisterman E, et al. Prognostic value of cardiac risk factors and coronary artery calcium screening for all cause mortality. Radiology. 2003;228:826\u201333.","journal-title":"Radiology"},{"key":"194_CR27","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1097\/00004872-200403000-00024","volume":"22","author":"J Shemesh","year":"2004","unstructured":"Shemesh J, Morag-Koren N, Goldbourt U, et al. Coronary calcium by spiral computed tomography predicts cardiovascular events in high-risk hypertensive patients. J Hypertens. 2004;22:605\u201310.","journal-title":"J Hypertens"},{"key":"194_CR28","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1001\/jama.291.2.210","volume":"291","author":"P Greenland","year":"2004","unstructured":"Greenland P, LaBree L, Azen SP, et al. Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals. JAMA. 2004;291:210\u20135.","journal-title":"JAMA"},{"key":"194_CR29","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1093\/aje\/kwi228","volume":"162","author":"MJ LaMonte","year":"2005","unstructured":"LaMonte MJ, FitzGerald SJ, Church TS, et al. Coronary artery calcium score and coronary heart disease events in a large cohort of asymptomatic men and women. Am J Epidemiol. 2005;162:421\u20139.","journal-title":"Am J Epidemiol"},{"key":"194_CR30","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.jacc.2005.05.049","volume":"46","author":"AJ Taylor","year":"2005","unstructured":"Taylor AJ, Bindeman J, Feuerstein I, et al. Coronary calcium independently predicts incident premature coronary heart disease over measured cardiovascular risk factors: mean three-year outcomes in the Prospective Army Coronary Calcium (PACC) project. J Am Coll Cardiol. 2005;46:807\u201314.","journal-title":"J Am Coll Cardiol"},{"key":"194_CR31","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jcmg.2009.03.009","volume":"2","author":"M Blaha","year":"2009","unstructured":"\u2022\u2022 Blaha M, Budoff MJ, Shaw LJ, et al. Absence of coronary artery calcification and all-cause mortality. J Am Coll Cardiol Img 2009;2:692\u2013700. This article provides a definitive demonstration of excellent prognosis of patients with a CAC score of 0.","journal-title":"J Am Coll Cardiol Img"},{"key":"194_CR32","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jcmg.2008.12.031","volume":"2","author":"A Sarwar","year":"2009","unstructured":"\u2022\u2022 Sarwar A, Shaw LJ, Shapiro MD, et al. Diagnostic and prognostic value of absence of coronary artery calcification. J Am Coll Cardiol Img 2009;2:675\u2013688. This article provides a definitive demonstration of excellent prognosis of patients with a CAC score of 0.","journal-title":"J Am Coll Cardiol Img"},{"key":"194_CR33","doi-asserted-by":"crossref","first-page":"b2376","DOI":"10.1136\/bmj.b2376","volume":"338","author":"JJ Brugts","year":"2009","unstructured":"Brugts JJ, Yetgin T, Hoeks SE, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ. 2009;338:b2376.","journal-title":"BMJ"},{"key":"194_CR34","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJM199511163332001","volume":"333","author":"J Shepherd","year":"1995","unstructured":"Shepherd J, Cobbe SM, Ford I, et al. For the west od scotland coronary prevention group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:301\u20137.","journal-title":"N Engl J Med"},{"key":"194_CR35","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","volume":"364","author":"HM Colhoun","year":"2004","unstructured":"Colhoun HM, Betteridge DJ, Durrington PN, et al. On behalf of the CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS):multicentre randomised placebo-controlled trial. Lancet. 2004;364:685\u201396.","journal-title":"Lancet"},{"key":"194_CR36","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.2337\/dc05-2415","volume":"29","author":"RH Knopp","year":"2006","unstructured":"Knopp RH, d\u2019Emden M, Smilde JG, Pocock SJ. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the atorvastatin study for prevention of coronary heart disease endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care. 2006;29:1478\u201385.","journal-title":"Diabetes Care"},{"key":"194_CR37","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","volume":"361","author":"PS Sever","year":"2003","unstructured":"Sever PS, Dahlof B, Poulter NR, et al. For the ASCOT investigators. Prevention of coronary and stroke events with atorvastatin inhypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial\u2014Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149\u201358.","journal-title":"Lancet"},{"key":"194_CR38","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1001\/jama.288.23.2998","volume":"288","author":"ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group","year":"2002","unstructured":"ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The antihypertensive and lipid-lowering treatment to prevent heart attack trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care. JAMA. 2002;288:2998\u20133007.","journal-title":"JAMA"},{"issue":"20","key":"194_CR39","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","volume":"279","author":"R John","year":"1998","unstructured":"John R, Downs JR, Michael Clearfield M, Weis S, et al. For the AFCAPS\/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS\/TexCAPS. JAMA. 1998;279(20):1615\u201322.","journal-title":"JAMA"},{"key":"194_CR40","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0140-6736(06)69472-5","volume":"368","author":"H Nakamura","year":"2006","unstructured":"Nakamura H, Arakawa K, Itakura H, et al. For the MEGA Study Group. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet. 2006;368:1155\u201363.","journal-title":"Lancet"},{"key":"194_CR41","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1161\/CIRCULATIONAHA.105.575241","volume":"113","author":"A Khera","year":"2006","unstructured":"Khera A, de Lemos JA, Peshock RM, et al. Relationship between C-reactive protein and subclinical atherosclerosis: The Dallas Heart Study. Circulation. 2006;113:38\u201343.","journal-title":"Circulation"},{"key":"194_CR42","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1001\/archinternmed.2010.182","volume":"170","author":"KK Ray","year":"2010","unstructured":"Ray KK, Seshasai SRK, Erqou S, et al. Statins and all-cause mortality in high-risk primary prevention. A Meta-analysis of 11 randomized controlled trials involving 65, 229 participants. Arch Intern Med. 2010;170:1024\u201331.","journal-title":"Arch Intern Med"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-011-0194-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11883-011-0194-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-011-0194-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T19:49:01Z","timestamp":1559418541000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11883-011-0194-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7,27]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["194"],"URL":"https:\/\/doi.org\/10.1007\/s11883-011-0194-z","relation":{},"ISSN":["1523-3804","1534-6242"],"issn-type":[{"value":"1523-3804","type":"print"},{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,7,27]]}}}